menu search

Mineralys therapeutics announces upcoming poster presentations at two scientific conferences in november 2023

Late-breaking poster presentation at ASN’s Kidney Week 2023 – – –Poster presentation at AHA’s Scientific Sessions 2023 RADNOR, Pa., Oct. 13,...

October 13, 2023, 8:10 pm

Mineralys therapeutics to announce second quarter 2023 financial results and host conference call on monday, august 7, 2023

RADNOR, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on deve...

July 31, 2023, 4:05 pm

aldosterone in congestive heart failure

Its contribution to the retention of sodium in patients with congestive heart failure, cirrhosis, and the nephrotic syndrome has also been established...

June 16, 2023, 1:59 pm

Mineralys therapeutics to announce first quarter 2023 financial results and host conference call on monday, may 15, 2023

RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on devel...

May 1, 2023, 8:00 am

Mineralys therapeutics to participate in the bank of america securities 2023 health care conference on wednesday, may 10, 2023

RADNOR, Pa., April 27, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on de...

April 27, 2023, 8:47 pm

Mineralys therapeutics announces pricing of upsized initial public offering

RADNOR, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on dev...

February 9, 2023, 11:34 pm

Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism

Hyperkalemia is a common occurrence in patients with congestive heart failure, particularly when renal failure coexists. The level of renal function i...

January 3, 2023, 8:14 am


Search within

Pages Search Results: